Elsevier

The Lancet

Volume 336, Issue 8706, 7 July 1990, Pages 1-6
The Lancet

MEDICAL SCIENCE
Xamoterol in severe heart failure

https://doi.org/10.1016/0140-6736(90)91517-EGet rights and content

Abstract

516 patients with New York Heart Association class III and IV heart failure despite treatment with diuretics and angiotensin converting enzyme inhibitors were randomised in a double-blind between-group comparison to xamoterol 200 mg (352) or placebo (164) twice daily for 13 weeks. There was no difference between the treatments in loss of clinical signs. Visual analogue scale and Likert scores indicated that breathlessness was less severe with xamoterol, but there was no difference in exercise duration or total work done. Xamoterol reduced maximum exercise heart rate and systolic blood pressure, did not affect the number of ventricular premature beats after exercise, showed no arrhythmogenic activity, and had variable (agonist and antagonist) effects on 24 h heart rate. On intention-to-treat analysis 32 (9·1%) patients in the xamoterol group and 6 (3·7%) patients in the placebo group died within 100 days of randomisation (p=0·02).

References (15)

There are more references available in the full text version of this article.

Cited by (489)

  • The Effect of inotropes and vasopressors on mortality: A meta-analysis of randomized clinical trials

    2015, British Journal of Anaesthesia
    Citation Excerpt :

    If we specifically consider acute or decompensated heart failure, the effect of inotropes is less defined. There are some evidences from observational studies that inotropes in general and catecholamines in particular could increase mortality.7–9 Moreover, in a meta-regression analysis, Thackray and colleagues11 found a non-significant increase in mortality associated with i.v. inotropes use, as compared with placebo or non-inotropic control.

  • Statistical Thinking for Non-Statisticians in Drug Regulation, THIRD EDITION

    2023, Statistical Thinking for Non-Statisticians in Drug Regulation, Third Edition
View all citing articles on Scopus
1

The names of organisers and participants are printed at the end of the paper. Correspondence to Prof Lars Rydén, MD, Division of Cardiology, Department of Medicine, Thoracic Clinics, Karolinska Hospital, S-104 01 Stockholm, Sweden.

View full text